Haisco(002653)2025-04-25 08:56Group 1: Product Development and Market Penetration - HSK31858 is expected to complete enrollment of over 600 participants by the second half of 2025 [3] - HSK21542 injection is anticipated to be approved for market entry in 2025 [3] - Both Kogrelitin and Clonazepam capsules have entered hundreds of secondary and higher-level hospitals [1] Group 2: Financial Performance and Projections - In Q1 2025, the company reported an 18% year-on-year increase in revenue, significantly exceeding the industry average [4] - The net profit attributable to shareholders decreased due to fluctuations in government subsidies, despite a 69% increase in net profit excluding non-recurring items [4] - R&D expenses accounted for approximately 39% of the total annual R&D budget in Q4 2024 [4] Group 3: Strategic Goals and Market Positioning - The company aims for innovative drugs to account for 40% of total sales by 2025 [3] - The focus will be on enhancing the commercialization capabilities of innovative drugs through academic promotion and brand building [6] - The company plans to expand its international market presence by selecting suitable overseas markets and product licensing [8] Group 4: R&D Investment and Pipeline - R&D investments over the past three years totaled over 2.8 billion CNY, with 2022, 2023, and 2024 investments at 958 million, 875 million, and 1 billion CNY respectively [8] - The company has 14 innovative drug projects in clinical stages, focusing on anesthesia, metabolic diseases, respiratory issues, and tumors [8] - The Protac platform has multiple drugs in early clinical stages, with ongoing IND applications [9]